Xeris Biopharma Holdings Inc

NASDAQ:XERS   4:00:00 PM EDT
1.41
+0.01 (+0.71%)
7:59:00 PM EDT: $1.42 +0.01 (+0.71%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)191.73M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$30.94 Million
Adjusted EPS-$0.15
See more estimates
10-Day MA$1.37
50-Day MA$1.46
200-Day MA$1.90
See more pivots

Xeris Biopharma Holdings Inc Stock, NASDAQ:XERS

180 North LaSalle Street, Suiite 1600, Chicago, Illinois 60601
United States of America
Phone: +1.844.445.5704
Number of Employees: 294

Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.